Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.
Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML patients are rarely cured by this therapy perhaps due to imatinib refractoriness of leukemia-initiating cells (LICs). Evidence for this is limited because of poor engraftment of human CML-LICs in NOD-SCID mice and nonphysiologic expression of oncogenes in retroviral transduction mouse models. To address these challenges, we generated mice bearing conditional knockin alleles of two human oncogenes: HIP1/PDGFbetaR (H/P) and AML1-ETO (A/E). Unlike retroviral transduction, physiologic expression of H/P or A/E individually failed to induce disease, but coexpression of both H/P and A/E led to rapid onset of a fully penetrant, myeloproliferative disorder, indicating cooperativity between these two alleles. Although imatinib dramatically decreased disease burden, LICs persisted, demonstrating imatinib refractoriness of LICs.
Pubmed ID: 19647224 RIS Download
Animals | Antineoplastic Agents | Benzamides | Core Binding Factor Alpha 2 Subunit | DNA-Binding Proteins | Disease Models, Animal | Drug Resistance, Neoplasm | Gene Knock-In Techniques | Genotype | Hematopoietic Stem Cells | Humans | Imatinib Mesylate | Leukemia, Myelomonocytic, Chronic | Mice | Mice, Transgenic | Myeloproliferative Disorders | Oncogene Proteins, Fusion | Piperazines | Pyrimidines | Spleen